- $6.11bn
- $9.76bn
- $1.90bn
- 77
- 38
- 85
- 74
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 661 | 1,171 | 1,196 | 1,458 | 1,902 |
Cost of Revenue | |||||
Gross Profit | 56.5 | 213 | 232 | 147 | 287 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Total Operating Expenses | 660 | 1,022 | 1,037 | 1,392 | 1,734 |
Operating Profit | 1.17 | 149 | 159 | 65.9 | 168 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | 0.76 | 149 | 158 | 65.1 | 169 |
Provision for Income Taxes | |||||
Net Income After Taxes | -1.59 | 118 | 124 | 50.9 | 121 |
Minority Interest | |||||
Equity in Affiliates | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -1.59 | 118 | 124 | 50.9 | 1.14 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -1.59 | 118 | 124 | 50.9 | 3.59 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.038 | 2.82 | 2.97 | 1.22 | 0.032 |
Dividends per Share |